Scancell Holdings Plc Japan patent for Moditope immunotherapy platform
08 April 2019 - 4:01PM
RNS Non-Regulatory
TIDMSCLP
Scancell Holdings Plc
08 April 2019
8 April 2019
Scancell Holdings Plc
("Scancell" or the "Company")
Scancell announces grant of Japan patent that protects its
Moditope(R) immunotherapy platform
Scancell Holdings plc, the developer of novel immunotherapies
for the treatment of cancer, today announces that the Japanese
Patent Office has granted a patent that provides protection for
Scancell's Moditope(R) immunotherapy platform.
Japanese patent number 6,490,581, entitled Anti-tumour Response
to Modified Self-epitopes, covers using any citrullinated
tumour-associated T cell epitope to treat patients with cancer. It
has a nominal expiry date of August 2033. This grant in Japan
follows the grant of patents in the US, Europe, South Africa and
Australia, and acceptance for grant in China. Counterparts to these
patents continue to be prosecuted in other territories of
importance to Scancell in order to further expand Scancell's IP
portfolio.
Dr Cliff Holloway, Chief Executive Officer, Scancell, said:
"We are pleased to announce the grant of this patent for
Moditope(R) in Japan, further extending our IP protection around
this platform. We look forward to continuing to advance Modi-1, the
first product from this platform, towards clinical
development."
For Further Information:
Scancell Holdings Plc
Dr John Chiplin, Chairman +44 (0) 20 3727 1000
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited
(Nominated Adviser and Corporate
broker)
Freddy Crossley/Emma Earl +44 (0) 20 7886 2500
FTI Consulting
Simon Conway/Natalie Garland-Collins +44 (0) 20 3727 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They can be used as
monotherapy or in combination with checkpoint inhibitors. This
platform has the potential to enhance tumour destruction, prevent
disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial has so far
successfully demonstrated survival data of more than five
years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents based on stress-induced
post-translational modifications (siPTM). It stimulates the
production of killer CD4 T cells which overcome the immune
suppression induced by tumours, allowing activated T cells to seek
out and kill tumour cells that would otherwise be hidden from the
immune system. Moditope(R) alone, or in combination with other
agents, has the potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of solid tumours
including triple negative breast cancer, ovarian cancer and head
and neck cancer.
For further details, please see our website:
www.scancell.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUBRORKWASRUR
(END) Dow Jones Newswires
April 08, 2019 02:01 ET (06:01 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024